The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.
 
Antonio Tito Fojo
Honoraria - Merck
Consulting or Advisory Role - Akita Biomedical; ElmediX (I); OnKure (I); PEGASCY (I); SERVIER (I)
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (I); Pfizer (Inst)
 
Mengxi Zhou
No Relationships to Disclose
 
Meredith LaRose
No Relationships to Disclose
 
Susan Elaine Bates
Honoraria - Merck (I)
Consulting or Advisory Role - Akita Biomedical (I); ElmediX; Ipsen; OnKure; Pegascy; Progenics (I); Secura Bio (I); SERVIER
Research Funding - Amgen (Inst); Ipsen (Inst); Merck (Inst); Pfizer; Pfizer (Inst); RenovoRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems